The global liquid biopsy for early cancer detection and monitoring market, valued at USD 2.18 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 11.62% from 2025 to 2034, driven by the urgent need for non-invasive, real-time cancer diagnostics and the integration of precision oncology into mainstream clinical practice. This expansion is shaped by stark regional...